The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Jul. 24, 4:24 AM

Slide #11. Puma Biotechnology, Inc. Secondary Offering

Company: Puma Biotechnology, Inc. (NYSE:PBYI)
Date announced: 2/11/2014
Shares Offered: 979,592
Date of Pricing: 2/11/2014
Price Per Share: $122.50
Secondary Offering Details: Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced the pricing of an underwritten public offering of 979,592 shares of its common stock at $122.50 per share. The Company has granted the underwriters for the offering a 30-day option to purchase up to 146,938 additional shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about February 14, 2014.

Puma Biotechnology is a development stage biopharmaceutical company that acquires and develops products for the treatment of several forms of cancer. Co. focuses on in-licensing drug candidates that are undergoing or has already completed initial clinical testing for the treatment of cancer and develop those drug candidates for commercial use. Co. is licensed the rights to three drug candidates: PB272 (neratinib (oral)), which it is developing for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; PB272 (neratinib (intravenous)), which it is developing for the treatment of advanced cancer patients; and PB357, which serves as a backup compound to PB272.
Open the PBYI Page at The Online Investor »

Company Name:  Puma Biotechnology, Inc.
Website:  www.pumabiotechnology.com
Sector:  Biotechnology
Number of ETFs Holding PBYI:  19
Total Market Value Held by ETFs:  $126.00M
Total Market Capitalization:  $1.78B
% of Market Cap. Held by ETFs:  7.09%
 

Open the PBYI Page at The Online Investor (in a new window) »

July 24, 2014    4:24 AM Eastern
Quotes delayed 20 minutes



Buy (3.33 out of 4)
64th percentile
(ranked higher than approx. 64% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.